What is GHK-Cu?
GHK is a short chain of three amino acids: glycine, histidine and lysine. It was identified in human blood and can bind copper. GHK-Cu is that copper-peptide complex. Research sometimes uses GHK without added copper, and sometimes a copper-containing formulation. The names should not be treated as interchangeable when interpreting a study.
The interest comes from effects on tissue-repair processes in laboratory experiments. The practical question is what happens when a defined product is used by people. Here, the evidence is more varied than a simple claim that GHK-Cu repairs or rejuvenates skin.
What have wound studies found?
A venous-ulcer trial found no advantage over the base cream. A 1992 randomized, evaluator-blinded trial enrolled 93 people, with 86 completing an evaluable course. It compared a copper-tripeptide cream, silver sulfadiazine cream and a vehicle control. The copper-peptide cream did not reduce ulcer size more than the vehicle. Silver sulfadiazine performed better in that study. Original trial.
A diabetic-ulcer study reported a positive result in a specific comparison. Mulder and colleagues enrolled 181 people across immediate and delayed treatment groups. Everyone received structured wound care. The immediate-treatment plantar-ulcer comparison involved 60 people and tested a particular copper-peptide gel. Median reduction in ulcer area was 98.5% with Iamin versus 60.8% with vehicle. That is a change in wound area, not the percentage of people completely healed. The delayed-treatment comparison did not show a closure-rate benefit. Treatment timing and ulcer type mattered, so the headline finding does not describe all 181 participants. 1994 study.
The development programme also went beyond that early study. ProCyte's subsequent annual report describes a 511-patient Phase III study and disappointing Iamin results in diabetic plantar ulcers. A complete primary clinical report of that later programme was not located for this review. That gap limits a detailed comparison, and the earlier positive result should not be presented as settled proof of wound-healing benefit. Sponsor filing.
What about wrinkles and other cosmetic outcomes?
Skin-biopsy changes are an early signal. A 1998 pilot involved 20 healthy volunteers, ten of whom applied a copper-peptide cream to one thigh and melatonin cream to the other. After one month, seven of the ten copper-peptide sites showed increased procollagen synthesis from baseline. This was a tissue marker, not a demonstration of visible wrinkle improvement or superiority over established treatment. Original study abstract.
Results after laser resurfacing were mixed. In a randomized 2006 study, 13 people completed follow-up after CO2 laser treatment around the mouth. GHK-Cu skin care did not significantly improve measured redness, wrinkles or overall skin quality compared with the control regimen. Patients using it reported greater improvement in skin quality. Their experience matters, but it differed from the blinded and objective assessments. Post-laser study.
A small wrinkle study favoured one formulation. A 2016 study assigned 40 women to two split-face comparisons over eight weeks. A GHK-Cu serum with a lipid carrier improved measured wrinkle outcomes compared with control serum, and wrinkle volume compared with another cosmetic product. However, the GHK-Cu product was always used on the right side. The control serum lacked both GHK-Cu and its carrier, so the study cannot separate their contributions. The serum manufacturer helped fund the work. Full study.
A 2026 eyebrow study adds a modest signal. Conference proceedings report a randomized, double-blind comparison in 18 adults with sparse eyebrows. Each person used GHK-Cu serum on one eyebrow and vehicle on the other for 12 weeks. At week 12, the treated side averaged about 1.8 more hairs in the measured one-square-centimetre area. Hair diameter and photographic scores also favoured treatment. The small sample and short follow-up leave the size, durability and wider usefulness of the effect uncertain. This was not a scalp-hair or whole-body rejuvenation study. Proceedings and full report.
What does the laboratory work add?
The widely repeated claim about thousands of genes needs context. A 2017 analysis used three existing gene-expression profiles from prostate and breast cancer cell lines exposed to GHK. It discussed genes relevant to nerve function, but did not treat people with neurological disease. Those findings do not show that injected GHK-Cu resets aging or repairs DNA in a person. Gene-analysis methods.
Formulation research is also useful. A 2023 experiment combined GHK-Cu with hyaluronic acid and measured collagen-related changes in cultured fibroblasts and skin samples outside the body. It found increased collagen IV measures with the tested combination. It did not measure wrinkles, wound closure or recovery in treated patients. Cell and skin-sample study.
What is the CuHeal trial?
CuHeal, NCT07437586, is a registered Phase 2 study planning to compare GHK-Cu gel with vehicle on paired small skin wounds in an estimated 60 healthy adults. The record lists recruiting, but its last posted update remains February 27, 2026. No results were posted when checked on November 9, 2026. The registration describes a study plan; it does not independently confirm enrollment or successful treatment. It is also not the first controlled human copper-peptide study. Current registry record.
How should safety and access be understood?
The topical studies cannot settle long-term or injected-use safety. In the 2016 wrinkle study, one participant stopped after mild reactions on both treated sides, which resolved. The 18-person eyebrow report recorded no adverse events over 12 weeks. Participants had skin patch testing before treatment; anyone who reacted would have been excluded. These are findings for those study products and participants.
For injections, FDA identifies potential immune-reaction risks from peptide aggregation and impurities, with limited human safety information. This review did not identify a controlled human trial establishing a systemic anti-aging or tissue-repair benefit from injected GHK-Cu. A cream study does not answer that question. FDA safety information.
In the United States, FDA's May 14, 2026 list places GHK-Cu except injectable routes in Category 1, meaning under evaluation for compounding. The injectable nomination was withdrawn. This is not drug approval or a finding that an injection is safe. GHK-Cu is not among the six substances listed in the October 2026 HHS peptide policy. FDA compounding list; HHS policy.
There is also a historical device clearance that needs its own explanation. FDA cleared Iamin-2 Hydrating Gel as a wound dressing in 1997. Its letter specifically prohibited claims that it accelerates wound healing or treats or cures wounds. That clearance does not approve today's GHK-Cu injections. Ordinary cosmetic sale is another separate matter: FDA generally does not approve cosmetics before marketing. Device clearance and limits; FDA cosmetics guidance.
Questions that make the evidence useful
The product
- Which exact peptide, copper complex and formulation is being proposed?
- Was that product tested by the same route?
The outcome
- Was the result a visible improvement, a wound measurement or a laboratory marker?
- How did it compare with the base cream or usual care?
The decision
- What are the established options for the actual skin or wound problem?
- What safety evidence and local authorization apply to this particular product?
Questions people ask
Has GHK-Cu been tested in people?
Yes. Controlled studies of topical copper-peptide products predate the current CuHeal registration by decades. Results differ across diabetic ulcers, venous ulcers, post-laser skin care and cosmetic formulations. Those studies do not establish a general benefit for every GHK-Cu product.
Do the skin studies support GHK-Cu injections?
No. Applying a particular cream or gel to skin does not establish the effects of an injected preparation. This review did not identify a controlled human study establishing a systemic anti-aging or tissue-repair benefit from injected GHK-Cu. FDA also identifies limited human safety data for the injectable route.
Does changing thousands of genes mean it reverses aging?
No. The widely cited gene analysis used existing data from cancer cell lines exposed to GHK. It did not show that people became younger, repaired DNA more effectively or regained nerve function after GHK-Cu treatment.
Does cosmetic sale or compounding status mean FDA approval?
No. Cosmetic sale, a device clearance and a compounding category are different regulatory matters. FDA lists non-injectable GHK-Cu under evaluation for compounding, while its injectable nomination was withdrawn. Neither establishes FDA drug approval or proves a clinical benefit.
What to take away
GHK-Cu has human topical research, including encouraging results and clear negative findings. The useful starting point is the exact product, condition and outcome studied. Those results do not establish that an injection produces the same effects or that a broad claim of rejuvenation is justified.
The evidence
Selected original studies, a sponsor filing and official sources. Related research is searchable on our Science page.
Sources checked November 9, 2026. Full texts were available for the 2016 and 2026 cosmetic reports and the gene analysis. The 1994 paper was checked through its author-uploaded text; the 1992 and 2006 papers through their original abstracts and available publisher text. The 1998 pilot was checked through its institutional abstract. A full clinical report of the later Phase III programme was not located. No article-specific medical review is claimed.
This article is for education and is not medical advice or a treatment recommendation. A qualified treating clinician should assess the condition, available treatments and the risks of any proposed product. Product availability and authorization depend on the jurisdiction and route of use. Any treatment decision should be made with a qualified physician. Individual results vary.